There is a risk of metastatic tumor formation for people with prostate cancer. A newly developed test can assess this risk more quickly than existing tests and is also cheaper to run.
According to the National Cancer Institute, about 11.2% of men will receive a prostate cancer diagnosis at some point in time.
In 2015 — the most recent year for which data are available — an estimated 3,120,176 men in the United States were living with prostate cancer.
Individuals with a first-time prostate cancer diagnosis and those who have undergone previous treatment for this form of cancer need to receive tests to determine their risk of metastasis.
If the risk of cancer spreading is high, the doctor may advise the person to proceed with a more aggressive type of treatment.
Researchers from the Albert Einstein College of Medicine in New York City, NY, have collaborated with colleagues from other research institutions to develop a new test for the assessment of metastasis risk. The new test, they say, is cheaper and faster than other methods currently available, and it requires only small tissue samples.
No comments:
Post a Comment